Mercados españoles abiertos en 7 hrs 28 min


Other OTC - Other OTC Precio demorado. Divisa en USD
Añadir a la lista de favoritos
74,00-6,10 (-7,62%)
Al cierre: 03:58PM EST


Allée de la Recherche, 60
Brussels 1070
32 2 559 99 99

Empleados a tiempo completo8600

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Jean-Christophe TellierCEO & Exec. Director4,49MN/A1959
Ms. Sandrine Dufour CFAExec. VP & CFON/AN/A1966
Ms. Kirsten Lund-JurgensenExec. VP of Supply & Technology SolutionsN/AN/A1959
Dr. Dhavalkumar D. Patel M.D., Ph.D.Exec. VP & Chief Scientific OfficerN/AN/A1961
Mr. William J. SilbeyExec. VP & Gen. CounselN/AN/A1959
Mr. Jean-Luc FleurialExec. VP & Chief HR OfficerN/AN/A1965
Prof. Iris Low-FriedrichExec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value PracticesN/AN/A1960
Mr. Emmanuel CaeymaexExec. VP of Immunology Solutions & Head of USN/AN/A1969
Mr. Charl van ZylExec. VP of Neurology Solutions & Head of EU/InternationalN/AN/A1967
Ms. Caroline VancoillieChief Accounting Officer & CFO of Patient Value FunctionsN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.


UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Gobierno corporativo

El ISS Governance QualityScore de UCB SA, a día 1 de diciembre de 2022, es 4. Las puntuaciones base son Auditoría: 1; Tablero: 6; Derechos de los accionistas: 1; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.